Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Bausch Health Companies Inc(BHC)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for BHC
09/24/2026: BHC (1-star) is a SELL. SELL for 3 days. Simulated Profits (-9.78%). Updated daily EoD!
Bausch Health Companies Inc is a specialty pharmaceutical firm focusing on gastroenterology, dermatology, and neurology. Its primary strength lies in an established portfolio of recognizable brands that generate consistent cash flow, such as Xifaxan. The main investment story centers on the company’s ongoing efforts to deleverage its balance sheet and focus R&D on high-need areas. However, investors face significant risks, including heavy debt obligations, ongoing legal liabilities, and the threat of patent cliffs on key revenue drivers. This stock may suit investors willing to accept high volatility in exchange for potential recovery, provided they closely monitor debt-refinancing progress and regulatory updates.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Weak fit | The company's focus is primarily on deleveraging rather than aggressive revenue or earnings growth. |
| Momentum investor | Mixed fit | Momentum is often tied to volatile news cycles regarding litigation or debt, making it highly speculative. |
| Value investor | Mixed fit | The valuation may appear depressed due to debt, but the quality of the balance sheet presents a significant value trap risk. |
| Dividend investor | Weak fit | The company does not pay a dividend and focuses on debt service. |
| Low-risk investor | Weak fit | High debt and legal uncertainties contribute to elevated stock price volatility. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock price is highly sensitive to regulatory news, litigation outcomes, and debt management updates. |
| Valuation risk | Medium / high | High debt levels complicate traditional valuation metrics, making it difficult to assess true underlying value. |
| Competition risk (generic entry) | High | The loss of patent protection for flagship products can drastically reduce revenue. |
| Business quality | Medium | While the product portfolio is established, the financial burden limits the quality of the investment thesis. |
| Dividend income | Low / none | There is no current dividend, providing no income to shareholders. |
| Execution risk | High | Management must successfully execute complex debt refinancing and operational restructuring. |
Price Behavior
Downtrend
The stock has experienced a sustained decline in price over recent periods.
Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit -43.09% | Avg. Invested days 35 | Today’s Advisory SELL |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/24/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.14B USD | Price to earnings Ratio - | 1Y Target Price 7.5 |
Price to earnings Ratio - | 1Y Target Price 7.5 | ||
Volume (30-day avg) 2.6M shares | Beta 0.37 | 52 Weeks Range 4.33 - 8.00 | Updated Date 09/23/2026 |
52 Weeks Range 4.33 - 8.00 | Updated Date 09/23/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.89 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Gastroenterology | Includes sales of Xifaxan and other GI-related products. | This is the company's most important revenue engine. |
| Dermatology | Includes various creams and medical dermatology products. | Provides secondary revenue but faces intense competition. |
| Geography | Operations in the US and international markets. | The US market remains the primary driver of profitability. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE - | Forward PE 1.33 | Enterprise Value 21.13B | Price to Sales(TTM) 0.2 |
Enterprise Value 21.13B | Price to Sales(TTM) 0.2 | ||
Enterprise Value to Revenue 1.95 | Enterprise Value to EBITDA 10.32 | Shares Outstanding 373.99M | Shares Floating 260.57M |
Shares Outstanding 373.99M | Shares Floating 260.57M | ||
Percent Insiders 11.12 | Percent Institutions 65.02 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Bausch Health Companies Inc
Exchange NYSE | Headquarters Laval, QC, Canada | ||
IPO Launch date 1994-03-29 | CEO & Director Mr. Thomas J. Appio | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 20300 | Website https://www.bauschhealth.com |
Full time employees 20300 | Website https://www.bauschhealth.com | ||
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company. It operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The company develops, manufactures, and markets products primarily in the therapeutic areas of gastroenterology, hepatology, neurology and dermatology, generic and branded generic pharmaceuticals, dentistry products, over-the-counter products, aesthetic medical devices, and eye health. The company sells its products in the United States, China, Canada, Poland, Mexico, France, South Korea, Russia, Japan, Germany, the United Kingdom, Spain, Italy, and internationally. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.